Neurimmune Sells Portion Of Its Royalty Interest In Cliramitug To Royalty Pharma For Up To $425M, Including $125M Upfront
Royalty Pharma PLC RPRX
$58.43
▼ -1.00%
($-0.59)
⬇️ Below Yest. Low
📅 Earnings This Week
Open
$58.63
Prev Close
$59.02
Day Range
$58.26 – $59.12
52W Range
$34.08 – $60.44
Market Cap
$33.65B
P/E (TTM)
40.67
Beta
0.43
Div Yield
1.59%
EPS (TTM)
$1.48
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-06-16 |
| Shares Out. | 575,830,000 |
| Website | royaltypharma.com/ ↗ |
| Phone | 12128830200 |
| Employees | 100 |
| Revenue | $630.6M |
| Gross Profit | $630.6M |
| Net Income | $468.3M |
| Total Assets | $19.82B |
| Total Liabilities | $9.88B |
| Equity | $9.94B |
About Royalty Pharma PLC
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Royalty Pharma PLC is a publicly traded company under the ticker symbol RPRX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
16 analysts (2026-07-01)